Agios Pharmaceuticals, Inc.AGIONASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank93
3Y CAGR+9.0%
5Y CAGR+10.4%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+9.0%/yr
vs -3.1%/yr prior
5Y CAGR
+10.4%/yr
Consistent
Acceleration
+12.1pp
Accelerating
Percentile
P93
Near historical high
vs 5Y Ago
1.6x
Solid growth
Streak
5 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $519.82M | +13.5% |
| 2024 | $458.07M | +12.1% |
| 2023 | $408.81M | +1.8% |
| 2022 | $401.58M | +11.7% |
| 2021 | $359.64M | +13.4% |
| 2020 | $317.14M | -41.6% |
| 2019 | $542.93M | +19.2% |
| 2018 | $455.47M | +25.2% |
| 2017 | $363.81M | +34.3% |
| 2016 | $270.88M | - |